Trials / Completed
CompletedNCT01455493
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-0980 | Oral daily dose |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-03-01
- Completion
- 2014-01-01
- First posted
- 2011-10-20
- Last updated
- 2016-08-11
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01455493. Inclusion in this directory is not an endorsement.